Journal of Community Hospital Internal Medicine Perspectives (Oct 2017)

Experience with ceftaroline for treatment of methicillin-resistant Staphylococcus aureus pneumonia in a community hospital

  • Apurwa Karki,
  • Craig Thurm,
  • Kelly Cervellione

DOI
https://doi.org/10.1080/20009666.2017.1374107
Journal volume & issue
Vol. 7, no. 5
pp. 300 – 302

Abstract

Read online

Background: Methicillin-resistant Staphylococcus aureus (MRSA) is an organism causing significant mortality and morbidity with nosocomial infections. Ceftaroline is a new cephalosporin antibiotic that has activity against MRSA. In the USA, this antibiotic has not been approved for use in pneumonia caused by MRSA. Objectives: To review the use of ceftaroline in MRSA pneumonia in a US hospital and evaluate its clinical success. Methods: A retrospective study was conducted in an urban community hospital assessing the use of ceftaroline for MRSA pneumonia. Results: The clinical success was comparable to the currently approved treatment for MRSA pneumonia. Conclusion: The results of our study showed a favorable result for the treatment of MRSA pneumonia. Well-designed studies need to be performed for further validation of these results.

Keywords